Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials. Issue 4 (3rd January 2018)

• Record Type: Journal Article
• Authors: Wang, Haining; Liu, Ye; Tian, Qing; Yang, Jin; Lu, Ran; Zhan, Siyan; Haukka, Jari; Hong, Tianpei
• Is Part Of: Diabetes, obesity & metabolism. Volume 20:Issue 4(2018)
• Page Start: 910
• Page End: 920
• Publication Date: 2018-01-03
• Subjects: dipeptidyl peptidase‐4 inhibitors -- GLP‐1 analogue -- incretins -- meta‐analysis -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13177
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Aims: To perform a meta‐analysis of randomized controlled trials (RCTs), including 6 recently published large‐scale cardiovascular outcome trials (CVOTs), to evaluate the risk of pancreatic cancer with incretin‐based therapies in patients with type 2 diabetes (T2DM). Materials and Methods: For the period January 1, 2007 to May 1, 2017, the PubMed, Embase, Cochrane Central Register andClininalTrials.gov databases were searched for RCTs in people with T2DM that compared incretin drugs with placebo or other antidiabetic drugs, with treatment and follow‐up durations of ≥52 weeks. Two reviewers screened the studies, extracted the data and assessed the risk of bias independently and in duplicate. Results: A total of 33 studies ( n = 79 971), including the 6 CVOTs, with 87 pancreatic cancer events were identified. Overall, the pancreatic cancer risk was not increased in patients administered incretin drugs compared with controls (Peto odds ratio [OR] 0.67, 95% confidence interval [CI] 0.44‐1.02). In the 6 CVOTs, 79 pancreatic cancer events were identified in 55 248 participants. Pooled estimates of the 6 CVOTs showed an identical tendency (Peto OR 0.65, 95% CI 0.42‐1.01). Notably, in the subgroup of participants who received treatment and follow‐up for ≥104 weeks, 84 pancreatic cancer events were identified in 59 919 participants, and a lower risk of pancreatic cancer was associated with incretin‐based therapies (Peto OR 0.62, 95% CI 0.41‐0.95). Conclusions: Treatment with incretin drugs was not associated with an increased risk of pancreatic cancer in people with T2DM. Instead, it might protect against pancreatic malignancy in patients treated for ≥104 weeks.